Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06095505

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

Led by Puma Biotechnology, Inc. · Updated on 2026-02-17

80

Participants Needed

30

Research Sites

194 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior lines of therapy. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to evaluate the efficacy, safety, and pharmacokinetics of alisertib.

CONDITIONS

Official Title

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 18 years or older at signing of informed consent
  • Pathologically confirmed small cell lung cancer
  • Prior treatment with one platinum-based chemotherapy and an anti-PD-L1 immunotherapy
  • Up to one additional systemic anti-cancer therapy for small cell lung cancer is allowed, for a total of up to two prior lines of therapy
Not Eligible

You will not qualify if you...

  • Prior treatment with an AURKA specific-targeted or pan-Aurora-targeted agent, including alisertib in any setting
  • Additional inclusion and exclusion criteria assessed by the study center

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 30 locations

1

Southern Cancer Center

Daphne, Alabama, United States, 36526

Actively Recruiting

2

The Oncology Institute of Hope and Innovation

Long Beach, California, United States, 90805

Actively Recruiting

3

Rocky Mountain Cancer Centers

Lone Tree, Colorado, United States, 80124

Actively Recruiting

4

Georgetown Lombardi Cancer Center

Washington D.C., District of Columbia, United States, 20057

Actively Recruiting

5

Clermont Oncology Center

Clermont, Florida, United States, 64711

Actively Recruiting

6

The Oncology Institute of Hope and Innovation

Fort Lauderdale, Florida, United States, 33316

Actively Recruiting

7

Moffitt Cancer Center

Tampa, Florida, United States, 33612

Actively Recruiting

8

Illinois Cancer Specialists

Niles, Illinois, United States, 60714

Actively Recruiting

9

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Indianapolis, Indiana, United States, 46202

Actively Recruiting

10

University of Maryland Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, United States, 21201

Actively Recruiting

11

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

Actively Recruiting

12

Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Actively Recruiting

13

Henry Ford Hospital

Detroit, Michigan, United States, 48202

Actively Recruiting

14

Minnesota Oncology Hematology

Burnsville, Minnesota, United States, 55337

Actively Recruiting

15

Nebraska Cancer Specialists

Grand Island, Nebraska, United States, 68803

Actively Recruiting

16

Oncology Hematology Care Clinical Trials

Cincinnati, Ohio, United States, 45226

Actively Recruiting

17

University Hospital - Cleveland Medical Center

Cleveland, Ohio, United States, 44106

Actively Recruiting

18

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Active, Not Recruiting

19

Zangmeister Cancer Center

Columbus, Ohio, United States, 43219

Actively Recruiting

20

Oncology Associates of Oregon

Eugene, Oregon, United States, 97401

Actively Recruiting

21

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States, 15232

Withdrawn

22

Medical University of South Carolina Hollings Cancer Center

Charleston, South Carolina, United States, 29425

Actively Recruiting

23

SCRI Oncology Partners

Nashville, Tennessee, United States, 37203

Actively Recruiting

24

Texas Oncology-Baylor Charles A. Sammons Cancer Center

Dallas, Texas, United States, 75246

Actively Recruiting

25

University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75390

Actively Recruiting

26

Oncology & Hematology Associates of Southwest Virginia

Blacksburg, Virginia, United States, 24073

Actively Recruiting

27

Universtity of Virginia Health System

Charlottesville, Virginia, United States, 22908

Completed

28

Virginia Cancer Specialists Research Institute

Fairfax, Virginia, United States, 22031

Actively Recruiting

29

Northwest Cancer Specialists

Vancouver, Washington, United States, 98686

Actively Recruiting

30

Marshfield Medical Center

Marshfield, Wisconsin, United States, 54449

Actively Recruiting

Loading map...

Research Team

P

Puma Biotechnology, Inc. Clinical Operations Senior Director

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here